| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
67,675 |
57,598 |
$1.39M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
13,632 |
11,839 |
$174K |
| 64483 |
|
1,583 |
1,187 |
$162K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,980 |
3,448 |
$134K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
5,157 |
4,612 |
$120K |
| 64635 |
|
1,045 |
555 |
$119K |
| 64493 |
|
1,458 |
822 |
$92K |
| 95886 |
|
1,015 |
860 |
$73K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
2,971 |
2,296 |
$60K |
| 80305 |
|
11,261 |
9,604 |
$60K |
| 64636 |
|
1,225 |
484 |
$55K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,415 |
2,721 |
$51K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,024 |
1,918 |
$37K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
545 |
452 |
$36K |
| 64494 |
|
1,394 |
786 |
$34K |
| 99408 |
|
4,940 |
4,175 |
$32K |
| 95911 |
|
311 |
276 |
$31K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
50 |
43 |
$22K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
430 |
374 |
$18K |
| 62323 |
|
171 |
130 |
$18K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,385 |
1,124 |
$10K |
| 96102 |
|
609 |
561 |
$8K |
| 95910 |
|
62 |
52 |
$5K |
| 96127 |
|
2,426 |
2,156 |
$4K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
63 |
63 |
$3K |
| 64495 |
|
127 |
92 |
$3K |
| 64640 |
|
16 |
12 |
$2K |
| 64479 |
|
12 |
12 |
$2K |
| 96146 |
|
3,341 |
2,700 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,373 |
1,116 |
$1K |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
96 |
87 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,883 |
2,652 |
$1K |
| 20610 |
|
35 |
27 |
$1K |
| 99406 |
|
166 |
148 |
$638.85 |
| 20611 |
|
16 |
15 |
$549.24 |
| 81025 |
|
51 |
48 |
$180.76 |
| G8428 |
Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given |
60 |
57 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
19 |
14 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
583 |
509 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
42 |
40 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
72 |
68 |
$0.00 |